Syneos Health (NASDAQ:SYNH) reported Q2 2018 earnings this Morning, coming in at $0.62 per share, beating Wall Street’s estimates of $0.61 per Share. Revenue for the quarter came in at $1.07 billion missing the streets estimates of $1.09 billion Recent Insider Trading for Syneos Health (NASDAQ:SYNH)
- On 1/22/2018 Christopher L Gaenzle, CAO, sold 1,470 with an average share price of $41.00 per share and the total transaction amounting to $60,270.00.
- On 9/18/2017 Alistair Macdonald, CEO, sold 2,348 with an average share price of $54.60 per share and the total transaction amounting to $128,200.80.
- On 9/18/2017 Christopher L Gaenzle, CAO, sold 4,682 with an average share price of $54.56 per share and the total transaction amounting to $255,449.92.
- On 9/18/2017 Gregory S Rush, CFO, sold 9,703 with an average share price of $54.48 per share and the total transaction amounting to $528,619.44.
- On 9/1/2017 Christopher L Gaenzle, CAO, sold 42,601 with an average share price of $58.67 per share and the total transaction amounting to $2,499,400.67.
- On 9/1/2017 Gregory S Rush, CFO, sold 88,739 with an average share price of $58.99 per share and the total transaction amounting to $5,234,713.61.
About Company Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina.Recent Analyst Rating for Syneos Health (NASDAQ:SYNH)
Recent Trading for Syneos Health (NASDAQ:SYNH) Shares of Syneos Health closed the previous trading session at with 1040600 shares trading hands.